Aromatase Inhibitors

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

By

Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.

Smoking Increases Risk of Adverse Events With Aromatase Inhibitor Therapy for Breast Cancer

Smoking Increases Risk of Adverse Events With Aromatase Inhibitor Therapy for Breast Cancer

By

Preoperative smoking is associated with increased risk for breast cancer events and distant metastasis in women treated with aromatase inhibitors (AIs). Hampering the utility of AIs, a common treatment for breast cancer, is yet another health risk associated with smoking.

ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase Inhibitors

ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase Inhibitors

By

The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.

Risk for Fatal Cardiovascular Events Not Increased in Patients With Breast Cancer Taking Aromatase Inhibitors

Risk for Fatal Cardiovascular Events Not Increased in Patients With Breast Cancer Taking Aromatase Inhibitors

By

Risk of the most serious cardiovascular events, cardiac ischemia and stroke, were not increased in breast cancer patients taking aromatase inhibitors compared with tamoxifen users.

Aromatase Inhibitor Users Want Information on Joint Adverse Events

Aromatase Inhibitor Users Want Information on Joint Adverse Events

By

Breast cancer survivors who are prescribed an adjuvant AI want ongoing communication with their oncology clinician about the potential for arthralgia and how these joint adverse effects can be managed.

Blood Test Indicates Breast Cancer Tumors Developed Resistance to Hormone Treatment

By

Scientists developed a highly sensitive blood test that indicates when breast cancers become resistant to standard hormone treatment. In addition, the test results can be used to guide further treatment.

Generic aromatase inhibitors may help breast cancer patients stick to therapy

Generic aromatase inhibitors may help breast cancer patients stick to therapy

Cost is a key factor for women to maintain their hormone treatment regimen, researchers report.

Acupuncture improves quality of life for breast cancer patients taking aromatase inhibitors (AIs)

By

Electroacupuncture (EA) produces significant improvements in fatigue, anxiety, and depression in as little as 8 weeks for patients with early stage breast cancer experiencing joint pain related to the use of aromatase inhibitors to treat breast cancer.

Adjuvant endocrine therapy and alopecia

Adjuvant endocrine therapy and alopecia

By

A patient on adjuvant endocrine therapy for breast cancer is complaining of hair loss. Could the alopecia be due to her endocrine therapy?

Paroxetine and chemoprevention drugs

Paroxetine and chemoprevention drugs

By

Can the drug paroxetine mesylate (Brisdelle, Paxil) be given to patients taking a chemoprevention drug such as raloxifene (Evista) or any of the aromatase inhibitors?

Biomarker shows when letrozole may stop breast cancer recurrence

By

A biomarker reflecting expression levels of two genes in tumor tissue has been found to predict which patients may be at risk for late recurrence of estrogen receptor (ER)-positive breast cancer, and when adjuvant letrozole therapy may be of benefit.

Questions about side effects? Your patients' perhaps not so surprising source for answers

Questions about side effects? Your patients' perhaps not so surprising source for answers

By

Many cancer patients go to the Internet with their questions about side effect management. But the information they glean is from reliable sources—other cancer patients.

Aromatase arthralgia a hot topic on breast cancer message boards

Online discussion of side effects associated with aromatase inhibitors is common and often related to drug-switching and discontinuation.

Annual report highlights 2012 cancer advances

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.

Treatment for breast cancer after menopause brings sexual difficulties

By

Women who receive aromatase inhibitors for breast cancer after menopause experience very high levels of sexual difficulties, including low interest, insufficient lubrication, and pain with intercourse, according to a recent study.

Tamoxifen soothes effects of prostate cancer treatment

The anti-estrogen tamoxifen appears to suppress gynecomastia and breast pain in men undergoing androgen-suppression therapy for prostate cancer.

Drug combination extends survival in metastatic breast cancer

Coadministration of anastrozole (Arimidex) and fulvestrant (Faslodex) improved survival in women with HR-positive metastatic breast cancer.

Extra weight reduces effectiveness of estrogen-suppressing therapy

Overweight women with breast cancer were found to have more estrogen remaining after hormone-suppressing therapy than did women of healthy weight.

Exemestane lowers "good" cholesterol levels

Exemestane significantly reduced invasive breast cancer in postmenopausal women at elevated risk, but the aromatase inhibitor also lowered HDL cholesterol levels.

Concurrent anastrozole/fulvestrant could be new first-line breast cancer treatment

Administering anastrozole (Arimidex) and fulvestrant (Faslodex) in combination rather than in sequence extended overall survival by 6 months in women with metastatic breast cancer, researchers reported at the CTRC-AACR San Antonio Breast Cancer Symposium.

Entinostat shows which users are most likely to have delayed breast cancer progression

Clinical outcome can be predicted shortly after administration of the HDAC inhibitor entinostat among women with metastatic breast cancer, according to the company that developed the agent.

Estrogen-lowering drugs improve surgical outcomes for breast cancer patients

By

Breast cancer patients who take estrogen-lowering drugs may avoid having to undergo mastectomy, according to a study to be presented at the Annual Meeting of the American Society of Clinical Oncology.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs